This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
23 Dec 2011

Baxter & Momenta Ink Biosimilars Pact

Baxter will make an upfront cash payment of $33 million to Momenta related to the collaboration for as many as six follow-on biologic compounds.

Baxter International and Momenta Pharmaceuticals have formed a collaboration for the development and commercialization of biosimilars.

 

Baxter will leverage its clinical development and biologic manufacturing expertise, as well as its sterile injectables and global commercial capabilities, while Momenta will provide its expertise in high-resolution analytics, characterization, and product and process development.

 

Baxter will make an upfront cash payment of $33 million to Momenta related to the collaboration for as many as six follow-on biologic compounds. Baxter may make additional payments over the next several years for the development of the compounds, contingent upon the achievement of technical, development and regulatory milestones with respect to all six pr

Related News